Description
Herceptin 150 mg contains Trastuzumab, a recombinant humanized monoclonal antibody that selectively binds to the HER2 (Human Epidermal Growth Factor Receptor 2) protein overexpressed in certain cancers. It is administered via intravenous infusion under the supervision of an oncologist.
🔬 Mechanism of Action
Trastuzumab binds to HER2 receptors on cancer cells and blocks the signaling pathways responsible for cell growth and division. In addition, it activates the immune system through antibody-dependent cellular cytotoxicity (ADCC), helping destroy cancer cells more effectively.
💊 Indications
Herceptin 150 mg is indicated for:
- HER2-positive early breast cancer (adjuvant and neoadjuvant therapy)
- HER2-positive metastatic breast cancer
- HER2-positive metastatic gastric or gastroesophageal junction cancer
- It is often used in combination with chemotherapy or other targeted therapies such as pertuzumab.
📌 Key Features of Herceptin 150 mg
- Strength: 150 mg
- Dosage Form: Injection / IV infusion
- Therapeutic Class: Anti-HER2 Monoclonal Antibody
- Administration: Intravenous infusion in a hospital or oncology clinic
- Monitoring: Regular cardiac function monitoring (LVEF assessment) required during treatment
⚕️ Benefits of Trastuzumab
- Targeted therapy specifically for HER2-positive cancers
- Improves progression-free and overall survival
- Effective in both early-stage and metastatic disease
- Standard of care in HER2-positive breast cancer treatment
⚠️ Precautions
- Risk of cardiotoxicity; cardiac monitoring required
- Infusion-related reactions may occur
- Not recommended during pregnancy
- Should be administered under oncologist supervision
Herceptin 150 mg (Trastuzumab Injection) is a cornerstone targeted therapy for HER2-positive cancers, helping improve treatment response and survival outcomes when used as part of comprehensive oncology care.
